AbbVie’s Humira Gains Tenth Indication in U.S.

AbbVie’s blockbuster therapy Humira has gone double digits with FDA-approved indications after the agency just approved the drug to treat non-infectious intermediate-, posterior- and pan-uveitis.

The approval marks Humira’s tenth indication in the U.S. for immune-mediated diseases, AbbVie says. It was first approved back in 2002.

Humira also picked up EU approval in June to treat non-infectious intermediate-, posterior- and pan-uveitis.